No Evidence of an Association Between Efavirenz Exposure and Suicidality Among HIV Patients Initiating Antiretroviral Therapy in a Retrospective Cohort Study of Real World Data

Medicine
Ella T NkhomaAngelina Villasis-Keever

Abstract

Recently, published studies have reported conflicting results regarding the association between efavirenz exposure and the risk of suicidality among patients with human immunodeficiency virus. The objective of this analysis was to compare the rate of suicidality among patients initiating efavirenz-containing versus efavirenz-free antiretroviral (ARV) regimens.This retrospective cohort study used US administrative claims data for commercially and Medicaid-insured individuals for the years 2006 to 2013. ARV-naive patients aged ≥12 years initiating an efavirenz-containing or efavirenz-free ARV regimen with ≥6 months of continuous insurance enrollment prior to ARV initiation were selected. The primary outcome was suicidality, defined as the occurrence of any medical claim with a diagnosis code for suicidal ideation or an inpatient or emergency department medical claim for suicide attempt. Unadjusted incidence rates were calculated and propensity score-adjusted hazard ratios were estimated to account for differences in patient characteristics.There were 19,983 patients (efavirenz-containing, n = 11,187; efavirenz-free, n = 8796) in the commercial database and 5154 patients (efavirenz-containing, n = 2224; efavirenz-free, n = 2930) i...Continue Reading

References

Oct 4, 2000·Social Psychiatry and Psychiatric Epidemiology·C IribarrenC Weisner
Jun 11, 2002·Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine·Timothy G HeckmanMonica Silverthorn
Jun 17, 2005·Journal of Behavioral Medicine·Nina A Cooperman, Jane M Simoni
Nov 4, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Félix GutiérrezAlberto Martín-Hidalgo
Apr 21, 2006·American Journal of Epidemiology·M Alan BrookhartTil Stürmer
Mar 21, 2007·Expert Opinion on Drug Safety·Gabriele ArendtThorsten Nolting
Oct 6, 2010·Pharmacoepidemiology and Drug Safety·Amanda R PatrickSebastian Schneeweiss
Apr 13, 2011·AIDS and Behavior·Christopher A Kenedi, Harold W Goforth
Jul 13, 2011·Psychology, Health & Medicine·Jose CatalanLorraine Sherr
Jul 26, 2011·Journal of Affective Disorders·Jayraan BadieeIgor Grant
Feb 16, 2013·Pharmacoepidemiology and Drug Safety·S Todd CallahanWilliam O Cooper
Nov 14, 2014·Journal of the International AIDS Society·Colette SmithJens Lundgren

❮ Previous
Next ❯

Citations

Aug 19, 2016·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Glenn J Treisman, Olivia Soudry
Aug 9, 2016·Expert Review of Clinical Pharmacology·Johannes P MoutonGary Maartens
Jun 12, 2019·JAMA : the Journal of the American Medical Association·UNKNOWN US Preventive Services Task ForceJohn B Wong
Jun 28, 2018·Pharmacological Reviews·Dhwanil A DalwadiJohn A Schetz
Jul 28, 2017·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Angela M BengtsonMichael J Mugavero
Sep 22, 2017·The Journal of Infectious Diseases·Katie R MollanUNKNOWN AIDS Clinical Trials Group
Mar 15, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Alejandro Arenas-PintoUNKNOWN INSIGHT START study group
May 12, 2021·American Journal of Epidemiology·Katie R MollanUNKNOWN CFAR Network of Integrated Clinical Systems and the AIDS Clinical Trials Group

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02211807

Software Mentioned

Stata
SAS
MP

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here